HIV

FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...

Clinical Diagnosis (Dx) is the identification and confirmation of disease or disorder or exposure to xenobiotics to explain the clinical manifestations shown by the patient. It is also performed to assess the state of health of an individual (routine health checkup), functioning of any organ or associated metabolic...

CereVasc Announces FDA Approval of Second IDE Study of the eShunt® System On August 09, 2022, CereVasc, Inc., a privately held, clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved ...

Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) that attacks the body’s immune system and obstructs the body’s ability to fight outer infections. The virus can be transmitted when contacted with infected blood, semen or vaginal fluids. HIV attacks the immune cells of the body ma...

The HIV-1 treatment market for naïve and experienced patients is evolving consistently. Some of the major changes include the preference of single-tablet regimens (STRs) over multiple tablet regimens (MTRs), tenofovir alafenamide (TAF)-based therapies over tenofovir disoproxil fumarate (TDF)-based therapies, integr...

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia ...

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Infectious diseases or communicable diseases are one of the leading causes of death worldwide. These diseases are spread by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi. Infectious diseases possess greater risk as these diseases can easily transfer from human to human or by other modes....